{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:45:56Z","timestamp":1789731956097,"version":"4.0.1"},"reference-count":54,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T00:00:00Z","timestamp":1488931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurogastroenterology Motil"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Micro\u2010inflammation is considered an element in the pathogenesis of irritable bowel syndrome (<jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content>). High\u2010sensitivity C reactive protein (hs\u2010<jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content>) was previously shown to be higher in <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content> compared to healthy controls, albeit within the normal range. Since probiotics may suppress micro\u2010inflammation in the gut, we tested if they reduce symptoms and inflammatory markers (hs\u2010<jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content> and fecal calprotectin (<jats:styled-content style=\"fixed-case\">FC<\/jats:styled-content>) in diarrhea\u2010predominant <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content>\u2010D). The aim of this study was to assess the clinical and laboratory effects of <jats:styled-content style=\"fixed-case\">BIO<\/jats:styled-content>\u201025, a multispecies probiotic, in women with <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content>\u2010D.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A double\u2010blind, placebo\u2010controlled study. Following a 2\u2010week run\u2010in, eligible women were assigned at random to a probiotic capsule or an indistinguishable placebo, twice daily for 8\u00a0weeks. <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content> symptoms and stool consistency were rated daily by Visual Analogue Scales (<jats:styled-content style=\"fixed-case\">VAS<\/jats:styled-content>) and the Bristol Stool Scale (<jats:styled-content style=\"fixed-case\">BSS<\/jats:styled-content>). High\u2010sensitivity C reactive protein was tested at baseline, 4 and 8\u00a0weeks. <jats:styled-content style=\"fixed-case\">FC<\/jats:styled-content> was tested at baseline and 8\u00a0weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key Results<\/jats:title><jats:p>One hundred and seventy\u2010two <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content>\u2010D patients were recruited and 107 eligible patients were allocated to the intervention (n=54) or placebo (n=53) group. All symptoms improved in both groups with no significant difference between them in symptom improvement, hs\u2010<jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">FC<\/jats:styled-content> levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions &amp; Inferences<\/jats:title><jats:p>An 8\u2010week treatment with <jats:styled-content style=\"fixed-case\">BIO<\/jats:styled-content>\u201025 improved symptoms in women with <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content>\u2010D, but was not superior to placebo. This rigorously designed and executed study supports the findings of other studies that did not demonstrate superiority of probiotics over placebo in <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content>. High quality clinical studies are necessary to examine the efficacy of other specific probiotics in <jats:styled-content style=\"fixed-case\">IBS<\/jats:styled-content>\u2010D patients since data are still conflicting.<\/jats:p><\/jats:sec>","DOI":"10.1111\/nmo.13037","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T09:52:56Z","timestamp":1488966776000},"source":"Crossref","is-referenced-by-count":64,"title":["A double\u2010blind, placebo\u2010controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea\u2010predominant <scp>IBS<\/scp>"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-7274","authenticated-orcid":false,"given":"K.","family":"Hod","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine School of Public Health Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"},{"name":"Research Division Epidemiology Service Assuta Medical Centers Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Sperber","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences Ben\u2010Gurion University of the Negev Beer\u2010Sheva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ron","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Liver Diseases Tel\u2010Aviv Sourasky Medical Center Affiliated to the Sackler Faculty of Medicine Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boaz","sequence":"additional","affiliation":[{"name":"Department of Nutrition Sciences School of Health Sciences Ariel University Ariel Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dickman","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Liver Diseases Rabin Medical Center Belinson Hospital Petach Tikva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Berliner","sequence":"additional","affiliation":[{"name":"Department of Medicine E Tel Aviv Sourasky Medical Center Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Halpern","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Liver Diseases Tel\u2010Aviv Sourasky Medical Center Affiliated to the Sackler Faculty of Medicine Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Maharshak","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Liver Diseases Tel\u2010Aviv Sourasky Medical Center Affiliated to the Sackler Faculty of Medicine Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dekel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Liver Diseases Tel\u2010Aviv Sourasky Medical Center Affiliated to the Sackler Faculty of Medicine Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02036.x"},{"key":"e_1_2_10_3_1","first-page":"541","article-title":"Mast cells in inflammatory conditions of the gastrointestinal tract","volume":"37","author":"Hiatt RB","year":"1962","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37059"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.33579"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.11.050"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.01.046"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.116"},{"key":"e_1_2_10_9_1","first-page":"307","article-title":"The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases","volume":"31","author":"Chaudhary NA","year":"1962","journal-title":"Q J Med"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-007-0074-3"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2011.01788.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000327"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2016.01.003"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.2650"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i10.3072"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04665.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12460"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.167270"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-016-0470-z"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01543.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2005.00695.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114515004043"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.9370"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.037325"},{"key":"e_1_2_10_25_1","unstructured":"CfDEaR (CDER).Guidance for Industry Irritable Bowel Syndrome \u2014 Clinical Evaluation of Products for Treatment.U.S. Department of Health and Human Services. Food and Drug Administration 2010.http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0069"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.4321\/S1130-01082009000800006"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i17.2067"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2010.02425.x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.4161\/gmic.2.2.15282"},{"key":"e_1_2_10_31_1","first-page":"576","article-title":"Clinical studies on alleviating the symptoms of irritable bowel syndrome","volume":"15","author":"Kajander K","year":"2006","journal-title":"Asia Pac J Clin Nutr"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e31823712b1"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00124.2010"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.4321\/S1130-01082013000100005"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000129271.98814.e2"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302167"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031951"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03818.x"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/45.12.2136"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta17550"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2013-100420"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00734.x"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.058"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000443362"},{"key":"e_1_2_10_45_1","first-page":"63","article-title":"Four years follow\u2010up of patients with irritable bowel syndrome","volume":"53","author":"Rusu F","year":"2015","journal-title":"Rom J Intern Med"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1027702"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03542.x"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2005.06.001"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04183.x"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-13-45"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gcb.2007.06.001"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12602-010-9059-y"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00086-8"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04087.x"},{"key":"e_1_2_10_55_1","first-page":"21","article-title":"Managing irritable bowel syndrome in primary care","volume":"259","author":"Corsetti M","year":"2015","journal-title":"Practitioner"}],"container-title":["Neurogastroenterology &amp; Motility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnmo.13037","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nmo.13037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T09:50:18Z","timestamp":1696240218000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nmo.13037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,8]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/nmo.13037"],"URL":"https:\/\/doi.org\/10.1111\/nmo.13037","archive":["Portico"],"relation":{},"ISSN":["1350-1925","1365-2982"],"issn-type":[{"value":"1350-1925","type":"print"},{"value":"1365-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,8]]},"article-number":"e13037"}}